Effect of Dexamethasone Premedication on Oral Mucositis in Hamster

被引:3
作者
Davarmanesh, M. [2 ]
Mardani, M. [2 ]
Mirkhani, H. [3 ]
Monabbati, A. [4 ]
Tanideh, N. [3 ,5 ]
Mehrabani, D. [1 ]
机构
[1] Univ Med Sci, Nemazee Hosp, Gastroenterohepatol Res Ctr, Shiraz, Iran
[2] Univ Med Sci, Nemazee Hosp, Fac Dent, Dept Oral Med & Diag, Shiraz, Iran
[3] Univ Med Sci, Nemazee Hosp, Dept Pharmacol, Shiraz, Iran
[4] Univ Med Sci, Nemazee Hosp, Sch Med, Dept Pathol, Shiraz, Iran
[5] Univ Med Sci, Nemazee Hosp, Comparat Med Res Ctr, Shiraz, Iran
关键词
Dexamethasone; prophylaxis; oral mucositis; hamster; NF-KAPPA-B; CARCINOMA-CELLS; MUCOSAL INJURY; INHIBITION; THERAPY; CANCER;
D O I
10.1080/09712119.2009.9707073
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
To determine the protective effect of dexamethasone on the course of an experimental oral mucositis, 75 male adult golden hamsters were randomly divided into five equal groups. The control group received no medication. The other four groups received 5-fluorouracil on days 1-2, one hour after daily injections of either normal saline or dexamethasone in three doses and continued till d9. Along 16 d of experimental period to cover oral mucositis resolution, all animals were blindly subjected to scratching by needle tips over the cheek pouches on d 4 to potentiate oral mucositis. Macroscopic assessments were performed on d 6, 9, 16 and microscopic assessments in sacrificed animals on days 9 and 16 using a valid scoring systems and a blood sampling for microbiological culture in two randomly selected animals from each group (d 9). A significant protective role of dexamethasone was observed at high and moderate doses on the course of oral mucositis development. Our findings showed that in the course of the current chemotherapeutic regimens, premedication of dexamethasone could effectively intervene against development of oral mucositis.
引用
收藏
页码:267 / 270
页数:4
相关论文
共 8 条
  • [1] Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
    Arlt, A
    Vorndamm, J
    Breitenbroich, M
    Fölsch, UR
    Kalthoff, H
    Schmidt, WE
    Schäfer, H
    [J]. ONCOGENE, 2001, 20 (07) : 859 - 868
  • [2] Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells
    Chuang, SE
    Yeh, PY
    Lu, YS
    Lai, GM
    Liao, CM
    Gao, M
    Cheng, AL
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 63 (09) : 1709 - 1716
  • [3] Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-κB
    Li, J
    Minnich, DJ
    Camp, ER
    Brank, A
    MacKay, SLD
    Hochwald, SN
    [J]. JOURNAL OF SURGICAL RESEARCH, 2006, 132 (01) : 112 - 120
  • [4] Effects of the tumour necrosis factor-α inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters
    Lima, V
    Brito, GAC
    Cunha, FQ
    Rebouças, CG
    Falcao, BAA
    Augusto, RF
    Souza, MLP
    Leitao, BT
    Ribeiro, RA
    [J]. EUROPEAN JOURNAL OF ORAL SCIENCES, 2005, 113 (03) : 210 - 217
  • [5] LITTLE JW, 2008, DENT MANAGEMENT MED, P451
  • [6] The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy
    Sonis, SL
    [J]. CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 2002, 13 (05) : 380 - 389
  • [7] Perspectives on cancer therapy-induced mucosal injury - Pathogenesis, measurement, epidemiology, and consequences for patients
    Sonis, ST
    Elting, LS
    Keefe, D
    Peterson, DE
    Schubert, M
    Hauer-Jensen, M
    Bekele, BN
    Raber-Durlacher, J
    Donnelly, JP
    Rubenstein, EB
    [J]. CANCER, 2004, 100 (09) : 1995 - 2025
  • [8] WOLVERTON SE, 2001, COMPREHENSIVE DERMAT, P112